342 related articles for article (PubMed ID: 20095915)
41. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
42. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Kruth J; Nissen J; Ernst T; Kripp M; Lukan N; Merx K; Hofmann WK; Hochhaus A; Hofheinz RD
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1845-51. PubMed ID: 20224968
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
[TBL] [Abstract][Full Text] [Related]
45. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
[TBL] [Abstract][Full Text] [Related]
46. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK
Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189
[TBL] [Abstract][Full Text] [Related]
47. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635
[TBL] [Abstract][Full Text] [Related]
48. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
Kim ST; Jang KT; Lee SJ; Jang HL; Lee J; Park SH; Park YS; Lim HY; Kang WK; Park JO
BMC Cancer; 2015 Jul; 15():530. PubMed ID: 26189560
[TBL] [Abstract][Full Text] [Related]
49. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
50. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
[TBL] [Abstract][Full Text] [Related]
51. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
52. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
54. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
[TBL] [Abstract][Full Text] [Related]
56. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
Gruenberger B; Schueller J; Heubrandtner U; Wrba F; Tamandl D; Kaczirek K; Roka R; Freimann-Pircher S; Gruenberger T
Lancet Oncol; 2010 Dec; 11(12):1142-8. PubMed ID: 21071270
[TBL] [Abstract][Full Text] [Related]
57. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study.
Androulakis N; Aravantinos G; Syrigos K; Polyzos A; Ziras N; Tselepatiotis E; Samonis G; Kentepozidis N; Giassas S; Vamvakas L; Georgoulias V
Oncology; 2006; 70(4):280-4. PubMed ID: 17047399
[TBL] [Abstract][Full Text] [Related]
58. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Verderame F; Russo A; Di Leo R; Badalamenti G; Santangelo D; Cicero G; Valerio MR; Gulotta G; Tomasello G; Gebbia N; Fulfaro F
Ann Oncol; 2006 Jun; 17 Suppl 7():vii68-72. PubMed ID: 16760298
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
